Evolus, Inc. is under investigation by Pomerantz LLP following an FDA warning about a misleading Instagram promotion for its wrinkle treatment Jeuveau. The FDA criticized the ad for downplaying safety risks and making exaggerated claims about the product's effectiveness. After the warning was disclosed on October 2, 2026, Evolus's stock fell 7.15% to $7.14 per share. The investigation will determine if Evolus and its executives engaged in securities fraud or other unlawful practices.
Evolus, Inc. is the subject of this news, provided here with related Health-sector market data from Pluang as of Nov 06, 2026 07:51 WIB. Among 150 priced Health-sector US stocks, only 18 rose while 132 fell. DNA (Ginkgo Bioworks Holdings Inc) dropped 14.16% to USD 10.00 with 100% buy orders and a typical hold time of 9 days, contrasting with ABCL (AbCellera Biologics Inc) which fell 13.11% to USD 10.67 but maintained 94% buy orders and a much longer hold time of 42 days. SLS (SELLAS Life Sciences Group Inc.) also declined 14.00% to USD 7.86, with a typical hold time of 11 days.
Ademi LLP is investigating Strategic Education for potential securities fraud related to inaccurate statements about its financials and business operations, particularly in Australia. This probe follows a more than 20% decline in the company's stock ...
Corporate Insight released research identifying top financial firms leading in customer-facing AI tools, including virtual assistants and AI-powered fintech platforms. Fidelity and Voya lead in retirement plan virtual assistants, while Lively excels ...
Strawberry Fields REIT announced a cash dividend of $0.17 per common share for the fourth quarter of 2026. The dividend will be paid on December 30, 2026, to shareholders recorded by December 16, 2026. The company specializes in owning and leasing he...
Syndax Pharmaceuticals is under investigation by Pomerantz LLP for possible securities fraud following the failure of its MAXPIRe Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis, which missed its primary endpoint. The trial news caused ...
Erasca, Inc. announced the termination of its Chief Operating Officer, Nicholas Chetwyn, effective November 2, 2026, as part of a leadership realignment to support its RAS-targeting programs. Following this announcement, Erasca's stock price fell nea...
